87 related articles for article (PubMed ID: 15537833)
21. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver.
Kassner N; Huse K; Martin HJ; Gödtel-Armbrust U; Metzger A; Meineke I; Brockmöller J; Klein K; Zanger UM; Maser E; Wojnowski L
Drug Metab Dispos; 2008 Oct; 36(10):2113-20. PubMed ID: 18635746
[TBL] [Abstract][Full Text] [Related]
22. The role of carbonyl reductase 1 in drug discovery and development.
Shi SM; Di L
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):859-870. PubMed ID: 28712324
[TBL] [Abstract][Full Text] [Related]
23. Differences in catalytic activity between rat testicular and ovarian carbonyl reductases are due to two amino acids.
Sciotti MA; Tam S; Wermuth B; Baker ME
FEBS Lett; 2006 Jan; 580(1):67-71. PubMed ID: 16359670
[TBL] [Abstract][Full Text] [Related]
24. Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1.
Miura T; Nishinaka T; Terada T
Mol Cell Biochem; 2008 Aug; 315(1-2):113-21. PubMed ID: 18493841
[TBL] [Abstract][Full Text] [Related]
25. Mapping of a novel human carbonyl reductase, CBR3, and ribosomal pseudogenes to human chromosome 21q22.2.
Watanabe K; Sugawara C; Ono A; Fukuzumi Y; Itakura S; Yamazaki M; Tashiro H; Osoegawa K; Soeda E; Nomura T
Genomics; 1998 Aug; 52(1):95-100. PubMed ID: 9740676
[TBL] [Abstract][Full Text] [Related]
26. S-nitrosoglutathione covalently modifies cysteine residues of human carbonyl reductase 1 and affects its activity.
Hartmanová T; Tambor V; Lenčo J; Staab-Weijnitz CA; Maser E; Wsól V
Chem Biol Interact; 2013 Feb; 202(1-3):136-45. PubMed ID: 23295225
[TBL] [Abstract][Full Text] [Related]
27. Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin.
Skarydová L; Skarka A; Novotná R; Zivná L; Martin HJ; Wsól V; Maser E
Toxicology; 2009 Oct; 264(1-2):52-60. PubMed ID: 19635524
[TBL] [Abstract][Full Text] [Related]
28. Two allelic variants of aldo-keto reductase 1A1 exhibit reduced in vitro metabolism of daunorubicin.
Bains OS; Takahashi RH; Pfeifer TA; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2008 May; 36(5):904-10. PubMed ID: 18276838
[TBL] [Abstract][Full Text] [Related]
29. Carbonyl reduction of mequindox by chicken and porcine cytosol and cloned carbonyl reductase 1.
Tang X; Mu P; Wu J; Jiang J; Zhang C; Zheng M; Deng Y
Drug Metab Dispos; 2012 Apr; 40(4):788-95. PubMed ID: 22266778
[TBL] [Abstract][Full Text] [Related]
30. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells.
Gonzalez B; Akman S; Doroshow J; Rivera H; Kaplan WD; Forrest GL
Cancer Res; 1995 Oct; 55(20):4646-50. PubMed ID: 7553643
[TBL] [Abstract][Full Text] [Related]
31. In vitro metabolism of the phosphatidylinositol 3-kinase inhibitor, wortmannin, by carbonyl reductase.
Holleran JL; Fourcade J; Egorin MJ; Eiseman JL; Parise RA; Musser SM; White KD; Covey JM; Forrest GL; Pan SS
Drug Metab Dispos; 2004 May; 32(5):490-6. PubMed ID: 15100170
[TBL] [Abstract][Full Text] [Related]
32. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
Yu A; Kneller BM; Rettie AE; Haining RL
J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554
[TBL] [Abstract][Full Text] [Related]
33. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
34. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1.
Olson LE; Bedja D; Alvey SJ; Cardounel AJ; Gabrielson KL; Reeves RH
Cancer Res; 2003 Oct; 63(20):6602-6. PubMed ID: 14583452
[TBL] [Abstract][Full Text] [Related]
35. Human carbonyl reductase (CBR) localized to band 21q22.1 by high-resolution fluorescence in situ hybridization displays gene dosage effects in trisomy 21 cells.
Lemieux N; Malfoy B; Forrest GL
Genomics; 1993 Jan; 15(1):169-72. PubMed ID: 8432528
[TBL] [Abstract][Full Text] [Related]
36. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.
Yi SY; Hong KS; Lim HS; Chung JY; Oh DS; Kim JR; Jung HR; Cho JY; Yu KS; Jang IJ; Shin SG
Clin Pharmacol Ther; 2004 Nov; 76(5):418-27. PubMed ID: 15536457
[TBL] [Abstract][Full Text] [Related]
37. Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5'-hydroxylation.
Iida I; Miyata A; Arai M; Hirota M; Akimoto M; Higuchi S; Kobayashi K; Chiba K
Drug Metab Dispos; 2004 Jan; 32(1):7-9. PubMed ID: 14709614
[TBL] [Abstract][Full Text] [Related]
38. Genomic sequence and expression of a cloned human carbonyl reductase gene with daunorubicin reductase activity.
Forrest GL; Akman S; Doroshow J; Rivera H; Kaplan WD
Mol Pharmacol; 1991 Oct; 40(4):502-7. PubMed ID: 1921984
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of xenobiotic N- and S-oxidation by variant flavin-containing monooxygenase 1 (FMO1) enzymes.
Furnes B; Schlenk D
Toxicol Sci; 2004 Apr; 78(2):196-203. PubMed ID: 14976351
[TBL] [Abstract][Full Text] [Related]
40. Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser.
Zolk O; Solbach TF; König J; Fromm MF
Drug Metab Dispos; 2009 Jun; 37(6):1312-8. PubMed ID: 19251820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
